We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
New Oncology Closes Financing Round
News

New Oncology Closes Financing Round

New Oncology Closes Financing Round
News

New Oncology Closes Financing Round

Read time:
 

New Oncology has announced the completion of a financing round to prepare the market launch of NEOliquid, a non-invasive blood test that identifies therapeutically actionable genome alterations in the circulating free tumour DNA (ctDNA) of cancer patients.

NEOliquid allows detection not only of mutations, but also of therapeutically relevant gene fusions (e.g. affecting ALK, ROS or RET kinases) with the highest sensitivity and confidence. Existing shareholders as well as additional investors participated in this financing round. Financial details were not disclosed.

“We are excited about the prospect of identifying therapeutically relevant genome alterations without the need to perform painful biopsies. This financing round is a critical step towards this important goal." commented Prof. Roman Thomas, founder of New Oncology.

Advertisement